Biogen’s MS Drug Wins FDA Approval as Intrasmuscular Injection
Biogen’s Plegridy (peginterferon beta-1a) has won FDA approval as an intramuscular injection for treating relapsing multiple sclerosis (MS).
The approval was supported by data showing the injectable drug reduced injection-site reactions by almost 18 percent when compared with subcutaneous administration.
Plegridy was first approved by the FDA in 2014 to treat MS via subcutaneous administration. The drug received European Medicines Agency approval for intramuscular injection in December.